Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization.
Ruffier d'Epenoux L, Barbier P, Fayoux E, Guillouzouic A, Lecomte R, Deschanvres C, Nich C, Bémer P, Grégoire M, Corvec S. Ruffier d'Epenoux L, et al. Among authors: nich c. JAC Antimicrob Resist. 2024 Oct 18;6(5):dlae163. doi: 10.1093/jacamr/dlae163. eCollection 2024 Oct. JAC Antimicrob Resist. 2024. PMID: 39429235 Free PMC article.
Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville É, Sotto A, Illes G, Chavanet P, Dubée V, Bleibtreu A, De Carné MC, Talarmin JP, Revest M, Castan B, Bellouard R, Dailly É, Allorge D, Dinh A, Le Turnier P, Gregoire M; Dalbavancin Pharmacokinetics (DALBAP) study group. Hervochon C, et al. J Antimicrob Chemother. 2023 Dec 1;78(12):2919-2925. doi: 10.1093/jac/dkad331. J Antimicrob Chemother. 2023. PMID: 37864551
Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.
Tessier E, Ruffier d'Epenoux L, Lartigue MF, Chaufour L, Plouzeau-Jayle C, Chenouard R, Guérin F, Tandé D, Lamoureux C, Bémer P, Corvec S; CRIOGO study group. Tessier E, et al. J Antimicrob Chemother. 2024 May 2;79(5):1045-1050. doi: 10.1093/jac/dkae071. J Antimicrob Chemother. 2024. PMID: 38507272
Effect of achieving bone sterilisation on bone architecture and bone marrow, in an experimental rabbit model of osteomyelitis caused by carbapenemase-producing Enterobacterales.
Davido B, Crémieux AC, Nich C, De Truchis P, Vaugier I, Gatin L, Tattevin P, Saleh-Mghir A. Davido B, et al. Among authors: nich c. Int J Antimicrob Agents. 2023 Dec;62(6):107003. doi: 10.1016/j.ijantimicag.2023.107003. Epub 2023 Oct 14. Int J Antimicrob Agents. 2023. PMID: 37839717 Free article.
Promoting Race and Ethnic Diversity in a Hospital-Based Randomized Clinical Trial to Address Untreated Alcohol Use Disorder: Initial Lessons Learned.
Edelman EJ, Frankforter T, Rojas-Perez OF, Ablondi K, Castro C, Corvino J, Garcia I, Gordon DM, Jaramillo Y, Johnson NL, Jordan A, Nich C, Paris M Jr, Pagano D, Weimer MB, Williams EC, Kiluk BD. Edelman EJ, et al. Among authors: nich c. J Addict Med. 2024 Nov 8. doi: 10.1097/ADM.0000000000001400. Online ahead of print. J Addict Med. 2024. PMID: 39514895
Improvement in coping skills from culturally-adapted digital CBT for Spanish-speaking Hispanics with substance use disorder: Secondary analysis of a randomized clinical trial.
Benitez B, Loya JM, Jaramillo Y, Muro-Rodriguez NJ, Rojas Perez OF, Nich C, Frankforter T, Paris M, Kiluk BD. Benitez B, et al. Among authors: nich c. J Subst Use Addict Treat. 2025 Jan;168:209536. doi: 10.1016/j.josat.2024.209536. Epub 2024 Oct 5. J Subst Use Addict Treat. 2025. PMID: 39374899 Clinical Trial.
187 results